About us

Cofounder of the company and MBA of National Taipei University, Mr. Chiu Jen-yi, with over 30 years of corporate management experience, specializes in the development and processing of various functional new materials. He was granted Kuokuang medal of 2007 National Invention Award, as well as honorary doctorate degree by Golden State University of the U.S.

After stints at Nan Ya Plastics and Chunglien Bedding, Mr. Chiu became a startup founder, having set up 50 companies, 20 of which still in operation, which span a wide range of businesses, including chemical engineering, textile, ceramic, agriculture, health, art, and medicine. Leading the company's professional team, Mr. Chiu aspires to make substantive contribution to the development of Taiwan's homegrown new medicines before his retirement.

Cofounder of the company, Dr. Chen Han-min has over 20 years in the research of biomedicine, specializing in biochemistry and enzyme chemistry. He is well versed in the production of monoclonal antibodies and medicine development via the approach of systems biology. In 2010, Dr. Chen developed ENERGI pharmaceutical technology platform, featuring the use of small molecule compounds in activating AMP activated protein kinase (AMPK), so as to adjust metabolism and thereby boost ATP, akin to cell energy, for the cure of diseases. Up to now, Dr. Chen has publicized over 50 SCI papers and obtained more than 10 patents, in addition to serving as reviewer for renowned international academic journals, such as Proteomics and Journal of Proteome Research.

After obtaining a doctorate degree in agricultural chemistry from National Taiwan University, Dr. Chen served as a postdoctoral researcher at the division of hematology and oncology, the Children's Hospital Los Angeles, affiliated with the University of Southern California, before returning to Taiwan to teach at Fu Jen Catholic University, where he has experienced such stints as the director of the Biophotonics Center and deputy dean of the College of Science and Engineering and is now professor jointly appointed by the Department of Life Science and the Graduate Institute of Applied Science and Engineering.

An initial member of the R&D team of Energenesis Biomedical, Dr. Lin Jiun-tsai has over 10 years of medical R&D experience, specializing in the screening and R&D of small-molecule pharmaceuticals for such diseases as liver cancer and neurodegenerative disease, for which he has publicized a number of papers and obtained multiple pharmaceutical patents. Dr. Lin is mainly responsible for formulating the development strategy for new medicines, patent deployment and IP management, and the development and production of dosage forms of trial drugs. With a doctorate degree from the Institute of Microbiology and Biochemistry, National Taiwan University, Dr. Lin previously served at the Institute of Biomedical Sciences, where he took part in the R&D for new medicines for Huntington's disease.

With over 20 years of financial management experience, Mr. Chiang Ming--tsan specializes in financial management, capital market, and financial planning, having assisted many companies in entering capital market and fund raising, on top of abundant experience helping companies with share listing, either on the centralized or the OTC markets. His cross-border financial management experience is conducive to him helping the company formulate strategy and cut corporate risk.

With a master's degree in finance from Fu Jen Catholic University, Mr. Chiang boasts abundant industrial experience, with stints at the IPO division of Taiwan International Securities, the financial division of Action Electronics, the financial division of Good Way Technology, and the equity investment division of Fuyi International Group, where he was in charge of financial management, assistance for several companies in share listing, and capital-market planning.

With over 10 years of medical R&D experience, Dr. Cheng Yi-fang specializes in the R&D on nucleic-acid medicines for various targeted therapies for cancer, having publicized a number of papers in this field. Joining Energenesis Biomedical in 2013, Dr. Cheng has taken in part in the R&D on medicines for multiple indications related to diabetes foot ulcer, abnormal hair loss, and cancer, in addition to take charge of application, planning, and management for clinical test.

With a doctorate degree from the Institute of Microbiology and Biochemistry, National Taiwan University, Dr. Yang served at the Institute of Biomedical Sciences, Academia Sinica, when she took part in the R&D on new nucleic-acid medicines for colon cancer and non-small-cell lung carcinoma.

Dr. Huang Chun-fang has nearly 20 years of experience in biomedical research, with expertise in cellular and molecular biology as well as in rodent behavioral analysis. With a doctorate degree from the Institute of Molecular Medicine, National Taiwan University and postdoctoral training in the Junger’s Center for Neuroscience Research, OHSU, USA, Dr. Huang previously worked at the National Laboratory Animal Center, NARLabs, Taiwan, where she led the effort to establish techniques for neuro-behavioral studies and served as study director for customized preclinical drug efficacy studies. Joined in 2020, Dr. Huang is mainly responsible for planning and overseeing in-house pre-clinical researches in Energenesis Biomedical.

With a bachelor degree in Accountancy from Fu Jen Catholic University, Ms. Chen served at Deloitte & Touche Taiwan Audit Function for 15 years, she has been providing audit service to many listed companies in Taiwan, and assisting clients for the IFRS implementation projects. Ms. Chen passed the CPA examination.

With years of accounting and auditing experience, Ms. Chen specializes financial statement audit, establishment of internal-control system, assist organizational risk management and taxation inspection.

After obtaining a bachelor's degree from China University of Science and Technology, Manager Chen worked at FAR EASTERN AI MAI CO., LTD, to provide company internal control system revision work and accounting workflow planning.